Plain-English translation of NCT02808572 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This research study is looking at two special proteins in your blood — osteoprotegerin and fibroblast growth factor 23 — that may be connected to heart disease risk in people with chronic kidney disease. Researchers want to understand whether measuring these proteins early on can help predict who might have heart problems later. By following you over several years, they hope to learn if these blood markers are useful warning signs.
People with chronic kidney disease have higher risks of heart disease and stroke, but doctors don't always know which patients are at greatest risk. This study exists to find new ways to spot danger early using blood tests, so that patients who need extra heart protection can be identified sooner.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn at the beginning of the study to measure the two bone-related proteins and check for signs of calcium buildup in your blood vessels. Then, over the next 7 years, researchers will keep track of whether you experience any heart-related events or health changes. You may have occasional follow-up visits or phone calls to record your health status, but this is mainly an observational study — you won't be taking any new medications as part of it.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
France